📌 Primary Results From ASCENT-03 ✨ PFS: 9.7 mo vs 6.9 mo, HR 0.62 ORR: 48% vs 46% DOR: 12.2 vs 7.2 mo OS immature: HR 0.98 PFS2: 18.2 vs 14.0, HR 0.70 Dr. @Javier Cortès at Proffered paper session 2 #ESMO25 🇩🇪 📍Berlin @oncoalert.bsky.social #OncoalertAF @nejm.org 🔗 lnkd.in/diBhSjXG

📌 Primary results from the randomised, phase III TROPION-Breast02 trial✨ 🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291 🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001 🔸 ≥5-month improvement in both median OS and PFS Proffered paper session 2 #ESMO25 @oncoalert.bsky.social #OncoalertAF

📌OncoAlert AF #ESMO25 @oncoalert.bsky.social See you in Berlin 🇩🇪

The OncoAlert Weekly Round Up is Now Out youtu.be/CSfTz6Iftek @realbowtiedoc.bsky.social @fernandoonco.bsky.social @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @drnataliagandur.bsky.social @barbaramelao.bsky.social @biagioricciutimd.bsky.social @erikahamilton9.bsky.social

The OncoAlert🚨NEWSLETTER ⭐️COMPLETE #ASCO25 EDITION ⭐️REGISTER 👉 oncoalert360.com 👉 buff.ly/48Xpgz0 @erikahamilton9.bsky.social @drsgraff.bsky.social @maryamlustberg.bsky.social @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @drnataliagandur.bsky.social @hoperugo.bsky.social

📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 🔗nejm.org/doi/full/10.10… 👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1) @oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc

@darcyburbage.bsky.social @crisbergerot.bsky.social @tingtingzhang.bsky.social @fionnualacrowley.bsky.social @oncoalert.bsky.social @weoncologists.bsky.social @elisabettabonzano.bsky.social @kjankovic.bsky.social @elisaagostinetto.bsky.social @joanmancusombc.bsky.social

📌 Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go? ✨Prof @icromeattini.bsky.social 👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️ @oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc

📌 NRG-BR003: A randomized phase Ill trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC. ✨Vicente Valero #ASCO25 @oncoalert.bsky.social #OncoAlertAF

📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer. ✨Erica L. Mayer, MD, MPH, FASCO ✔️Rapid Oral Abstract Session Breast Cancer-Local/Regional/ Adjuvant @oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3

📌 Highlights of the Day II 👉🏻Breast Cancer-Metastatic ✨@maryam_lustberg 👏🏻 🟩 Key takeaways HR+ MBC 🟦 Key takeaways in HER2 positive MBC 🟨 Key Takeaways Metastatic TNBC @oncoalert.bsky.social #OncoAlertAF #ASCO25

📌 Do We "Node" What to Do About the Axilla❓ Great discussion👏🏻 ✨Mediget Teshome, MD, FACS, MPH @oncoalert.bsky.social #OncoAlertAF #ASCO25

📌 LBA Session❗️ ✨DESTINY-Breast09 results ✅ Stunning presentation ✨ @stolaney1.bsky.social 👏🏻 👉🏻 Median PFS: 🔸T-DXd + P: 40.7 mo 🔸THP: 26.9 mo HR 0.56, p<0.001 👉🏻ORR 85.1% @oncoalert.bsky.social #OncoAlertAF #ASCO25

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 @elisaagostinetto.bsky.social ‬ @erikahamilton9.bsky.social ‬ @drsgraff.bsky.social ‬ @elisabettabonzano.bsky.social ‬

📌Great discussant #ESTRO25 prof @icromeattini.bsky.social 👏🏻👏🏻 ✨ Late-Breaking Papers ✨ 👉🏻10y FAST-Forward randomised trial 👉🏻 DBCG Skagen trial 1 @oncoalert.bsky.social

@biagioricciutimd.bsky.social @drnataliagandur.bsky.social @barbaramelao.bsky.social @elisabettabonzano.bsky.social @kjankovic.bsky.social @elisaagostinetto.bsky.social @oncoalert.bsky.social @weoncologists.bsky.social

A Great Presentation by Dr. Hope Rugo 🇺🇸 on Advanced Triple Negative #BreastCancer 🚨 vimeo.com/1077243852?s... Get caught up on the TOP trials and those that impacted Clinical Practice in less than 2⃣0⃣min You Can find ALL video here, Free & On Demand👇 oncoalert360.com/oncoalert128...

📌Proud to share our latest review: “Current Treatment Paradigms for Advanced Melanoma with Brain Metastases” 🧠 mdpi.com/1422-0067/26/8… 👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies. @oncoalert.bsky.socia#OncoAlertAFAF

The @oncoalert.bsky.social 🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025 REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... youtu.be/l_jcTe69cCs

📌 Awareness of genomic testing among patients with breast cancer in Europe 🧬 www.sciencedirect.com/science/arti... @oncoalert.bsky.social #OncoAlertAF @breastdocuk.bsky.social @csabadegi.bsky.social

📌 Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial @oncoalert.bsky.social #OncoAlertAF thegreenjournal.com/article/S0167-…

📌 Selective Elimination of Breast Surgery for Invasive Breast Cancer A Nonrandomized Clinical Trial jamanetwork.com/journals/jam... @oncoalert.bsky.social

📌 Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer jamanetwork.com/journals/jam... @oncoalert.bsky.social

📌 Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism molecularcancer.biomedcentral.com/articles/10.11… @oncoalert.bsky.social

📌 Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer 👉🏻 addressing lifestyle factors to improve patient outcomes and quality of life 🚭 ro-journal.biomedcentral.com/articles/10.11… @oncoalert.bsky.social

🚨New #VJOncoAlertJournalClub! with @oncoalert.bsky.social 🗞️ Breaking down the latest in #oncology – every week! Join Misty Shields as she shares the latest advances in #SCLC, including the game-changing #ADRIATIC trial, DLL3-targeting therapies & more www.vjoncology.com/video/ayudqc...

📌 Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation sciencedirect.com/science/articl… @oncoalert.bsky.socia#OncoAlertAFAF

Development of a prediction model for ctDNA detection (Cir-Predict) in #BreastCancer buff.ly/6Ixw2Jy This study developed a prediction model, Cir-Predict, to assess the detectability of circulating tumor DNA (ctDNA) in breast cancer patients

Effect of BMI on #BreastCancer stage and #BreastCancer specific survival link.springer.com/article/10.1... Findings highlight the need for more comprehensive assessments of body composition and metabolic health in BC patients. @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social

📌 Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial redjournal.org/article/S0360-… @oncoalert.bsky.social

Oncology HERE & NOW Webcast/Podcast Now Out, JOIN OncoAlert Faulty🚨 Dr. @elisaagostinetto.bsky.social 🇧🇪& Dr. @maryamlustberg.bsky.social 🇺🇸 as they dive into #BreastCancer and the use of adj CDK 4/6 inhibitors and more youtu.be/zw8vYd894jI Podcasts : buzzsprout.com/1324033/epis...

Now out a new episode of Oncology Here&Now, a podcast by @oncoalert.bsky.social 🎙️ I had the pleasure to discuss with @maryamlustberg.bsky.social about adjuvant CDK4/6i, including: 🔸how to choose between abema and ribo 🔸how to manage progression during or after adj CDK4/6i 🔸Male breast cancer!

📌Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial @oncoalert.bsky.social

Planning Automation for Treatment Techniques Comparison and Robustness Analysis: Tangential IMRT and VMAT for Whole Breast Irradiation #BreastCancer #medphys #radonc #OncoAlert @oncoalert.bsky.social Free 50-day link: www.advancesradonc.org/article/S245...

📌 Comparison of 18F-FET-PET- and MRI-based target definition for re-irradiation treatment of recurrent diffuse glioma 🧠 sciencedirect.com/science/articl… @oncoalert.bsky.social

📌 Pre-Operative Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer Patients with Gammapod Technology: Pathological Findings and Ki-67 Evaluation redjournal.org/article/S0360-… @oncoalert.bsky.social

📌 Long-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery @oncoalert.bsky.social #OncoAlertAF @ijrobp.bsky.social #BreastCancer

📌 Whole genome sequencing powered ctDNA sequencing for breast cancer detection annalsofoncology.org/article/S0923-… @oncoalert.bsky.social

Day Three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/42IcWl2 Fatima Cardoso 🇵🇹 👏🏻 of @ABCGlobalAll Covering Brain Metastasis in Breast Cancer: Year in Review @oncoalert.bsky.social

Day Three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4gsEa2f prof @icromeattini.bsky.social 🇮🇹 👏🏻 Radiation Oncology in Breast Cancer: Year in Review @oncoalert.bsky.social

Day Three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4hnnLgR prof @matteolambe 👏 @SanMartino_Ge @Unige Covering Fertility Preservation- Breast Cancer: Year in Review @oncoalert.bsky.social

Day3⃣ #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 https://buff.ly/40XzdKp @E_de_Azambuja 🇧🇪 of @JulesBordet Covering Early HER2+ Breast Cancer: Year in Review REGISTER NOW for a Live chat with Dr. de Azambuja

Day Three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/3ErKrxY @kevinpunie 🇧🇪 of @mybsmo Covering Early TNBC Breast Cancer: Year in Review @oncoalert.bsky.social

Day Three #OncoAlertColloquium 🚨 #BreastCancerREGISTER for FREE HERE📷buff.ly/4jE6uBT @E_de_Azambuja 👏 of @julesbordet Covering Early HER2+ Breast Cancer: Year in Review @oncoalert.bsky.social

Day Two #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 https://buff.ly/42IZcXu @hannahrwardill @PaoloBossi6 of @CancerCareMASCC Covering Mucositis in Review REGISTER NOW for a Live chat with Dr. Wardill and Dr. Bossi

Day three #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4aUryQA @hoperugo.bsky.social 👏🏻🇺🇸 of UCSF Covering Advanced #TNBC : Year in Review @oncoalert.bsky.social

Day Three #BreastCancer #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 buff.ly/4gmAhw1 @drsgraff.bsky.social 👏🏻🇺🇸 HER2+ Metastatic Breast Cancer @oncoalert.bsky.social

Day One #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 https://buff.ly/4hXflwT @VincentWenxinXu 🇺🇸 of @DanaFarberNews Doing #KidneyCancer in Review REGISTER NOW for a Live chat with Dr. Xu

Day One #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 https://buff.ly/4jJ0sj9 @RenuEapen & @declangmurphy 🇦🇺of @gu_onc Doing #Urology in Review & Controversial Topics REGISTER NOW for a Live chat with Drs. Eapen & Murphy

📌Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trial sciencedirect.com/science/articl… @oncoalert.bsky.social